Molecular alterations like MSI (15–30%) and like BRAF (~10%) and KRAS (~10–25%) mutations are linked with UC-associated CRC and contribute to damage of mucosal barriers, which further leads to UC-associated mucosal neoplasia. Here, KRAS is linked to colorectal carcinoma.